Full Press Release Details
Dr. Matushansky has served as our Chief Medical Officer since March 2025. Prior to joining Immuneering, Dr. Matushansky served as Chief Medical Officer at Sail Biomedicines, a Flagship Pioneering biotechnology company, from July 2023 to January 2025, where he built out and led the clinical/medical, translational, operational and regulatory functions. Prior to that, Dr. Matushansky was SVP and Global Head of Oncology Development at Ipsen S.A., a global specialty-care biopharmaceutical company, from July 2022 to June 2023, where, among other programs, he oversaw the completion of NAPOLI-3 leading to the approval of NALIRIFOX for first-line pancreatic cancer. Dr. Matushansky also served as Chief Medical Officer and Global Head of Research and Development at Hookipa Pharma Inc., a biopharmaceutical company, from April 2017 to July 2022, where he was responsible for bringing novel arenavirus technology from early preclinical research to clinical proof-of-concept. He also served as Global Head of Oncology Early Development at Daiichi Sankyo from November 2015 to April 2017, leading the company’s international research unit focused on early oncology therapeutic programs, and was Global Head at the Gene & Cell Therapy Unit and earlier the Global Clinical Program Head within the Oncology Translational Medicine Unit at Novartis from June 2012 to November 2015. Dr. Matushansky began his career in academia at the Columbia University Medical Center, where he founded and directed a sarcoma center and ran a laboratory focused on the molecular basis of sarcomas. Dr. Matushansky continues to dedicate time treating sarcoma patients as an attending physician. Dr. Matushansky earned his B.A. from Columbia University and his M.D. and a Ph.D. in molecular biology from Albert Einstein College of Medicine. Dr. Matushansky performed his internal medicine residency at New York Presbyterian Hospital/Weill Cornell Medical Center, and completed a fellowship in medical oncology and a post-doctoral research fellowship in cancer biology at the Memorial Sloan Kettering Cancer Center.